United States

People: OPKO Health Inc (OPK.O)

OPK.O on Nasdaq

21 Aug 2019
Change (% chg)

$0.02 (+1.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Rubin, Steven 

Mr. Steven D. Rubin serves as Executive Vice President - Administration, Director of the Company. Mr. Rubin has served as Executive Vice President – Administration since May 2007 and as a director of the Company since February 2007. Mr. Rubin currently serves on the board of directors of Red Violet, Inc. (NASDAQ CM:RDVT), a software and services company, Non-Invasive Monitoring Systems, Inc. (OTC US:NIMU), a medical device company, Cocrystal Pharma, Inc. (NASDAQ GM:COCP), a publicly traded biotechnology company developing new treatments for viral diseases, Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical stage biopharmaceutical company dedicated to treating patients suffering from rare and ultra-rare disease caused by premature termination codon nonsense mutations, Castle Brands, Inc. (NYSE American:ROX), a developer and marketer of premium brand spirits, Neovasc, Inc. (NASDAQ CM:NVCN), a company that develops and markets medical specialty vascular devices, and ChromaDex Corp. (NASDAQ CM:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age. Mr. Rubin previously served as a director of VBI Vaccines, Inc. (NASDAQ CM:VBIV), a biopharmaceutical company developing next generation vaccines, BioCardia, Inc.(OTC US:BCDA), clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases, Cogint, Inc. (NASDAQ GM:COGT), now known as Fluent, Inc. (NASDAQ:FLNT), an information solutions provider focused on the data-fusion market, prior to the spin-off of its data and analytics operations and assets into Red Violet, Inc., Kidville, Inc. (OTCBB:KVIL), which operates large, upscale facilities, catering to newborns through five-year-old children and their families and offers a wide range of developmental classes for newborns to five-year-olds, Sevion Therapeutics, Inc., prior to its merger with Eloxx Pharmaceuticals, Inc., Dreams, Inc. (NYSE American:DRJ), a vertically integrated sports licensing and products company, SciVac Therapeutics, Inc.

Basic Compensation

Total Annual Compensation, USD 810,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 650,000
Fiscal Year Total, USD 1,460,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 265,000 1,404,500.00
Name Fiscal Year Total

Phillip Frost


Geoff Monk


Jane Hsiao


Adam Logal


Jon Cohen


Steven Rubin

As Of  30 Dec 2018